hotspot -WSS

hotspot

author：focus 2025-09-27 10:02:04 - browse：444

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Novo: Oral version of Ozempic leads to 15% weight loss

focus

knowledge

WSS

ALS treatment from Biogen, Ionis fails in study

CVS is willing to dump 10% of its Medicare Advantage members

What a koala virus tells us about the human genome

The thinking behind the controversial eating disorder chatbot Tessa

Free medical tuition alone isn't enough to close gaps in primary care

Novo: Oral version of Ozempic leads to 15% weight loss

hotspot

hotspot

leisure time

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Novo pauses ads for weight loss drug Wegovy amid demand

How one medical school became remarkably diverse

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

In Memoriam: Notable people who died in 2023

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Tori Bowie and the unacceptable rates of Black maternal death

As H5N1 spreads in cows, experts warn against drinking raw milk

The cancer drug shortage isn’t new — and neither are the solutions

Fertility clinic egg and embryo storage is a disaster

hotspot

Free medical tuition alone isn't enough to close gaps in primary care

STAT reporters are Pulitzer Prize finalists for investigative reporting

HHS suspends federal funding for EcoHealth Alliance

Altering the blood type of lungs raises potential for universal organs for transplants

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Mom launches Girl Scout troop for LGBTQ youth in Texas

focus

knowledge

entertainment

focus